0.00
-33.33%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Adalta
Its shares trade on ASX under the ticker 1AD.AX. It has been listed since 22 August 2016. In the fiscal year to 30 June 2025, it reported revenue of A$677,010 and a net loss of A$4.5m. At that date it held total assets of A$2.1m and shareholders' equity of −A$598,244.
AdAlta Ltd. operates as a biotechnology company, discovers, develops, and commercializes protein based therapeutics. The firm is engaged in the development of therapeutic products from its i-body platform. The firm has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patient’s immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patient’s immune system to recognize and kill diseased cells such as cancer. The company develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. The company evaluates several CXCR4 i-bodies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 22 Aug 2016
- Website
- adalta.com.au ↗
Leadership
Pay as last reported
- Dr. Paul MacLemanNon-Executive Chairman of the Board, since 2015A$135,806
- Dr. Timothy OldhamChief Executive Officer, Managing Director, Executive Director, since 2019A$484,544
- Dr. Michael FoleyChief Scientific Officer
- Mr. Cameron JonesCompany Secretary
- Ms. Michelle BurkeNon-Executive Director
- Dr. David FullerNon-Executive DirectorA$73,884
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Adalta Ltd. develops AD-214 for fibrotic diseases including IPF and ILD in Phase II trials.
- Adalta's i-body platform supports five active development programs in inflammation/fibrosis and immuno-oncology.
- Adalta's i-PET imaging agents are used in immuno-oncology for diagnostic purposes.
Weaknesses
- Adalta has no products approved for commercial use as of 2023.
- Adalta's development programs are in early to mid-stage clinical trials without market approval.
- Adalta's lead product AD-214 is still in Phase II clinical trials without regulatory approval.
Opportunities
- Adalta's CXCR4 i-bodies could expand into new therapeutic areas beyond current focus.
- Adalta's i-body platform may attract partnerships with larger biotech firms for development funding.
- Adalta's immuno-oncology focus aligns with growing market demand for cancer treatments.
Threats
- Adalta faces competition from established biotech companies in the immuno-oncology sector.
- Regulatory delays could impact the timeline for AD-214's approval in fibrotic diseases.
- Clinical trial failures could halt progress in Adalta's five development programs.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.